الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 114 |  |  |
| | | from | 114 | | |
Abstract
Chronic back pain is a growing economic and healthcare issue. Approximately 90% of the population will have back discomfort impacting normal activity, function, or both over their lives. One cause of prolonged back pain is LSCS. The lumbar canal is narrowed by disc degeneration, osteophytes, and facet joint inflammation. LSCS is based on a ”mechanical block” neurovascular process. Direct compression in the central canal with hypertrophy ligamentum flavum or cauda equina arterial flow are possible mechanisms. LSCS can be treated surgically or non-surgically through medication, physical therapy and local injection. Local injection is a typical non-surgical therapy for LSCS, especially for patients who are unsuited for surgery, refuse surgery, or have no response to medicinal therapies after 6 months. ESI attempt to decrease pain response and enhance function. These injections have anti-inflammatory properties. ESI provide medicine at the site of discomfort generation. ESI is a corticosteroid and a local anesthetic pain relief medicine that relieves the pain within short time. An ESI can give pain relief alone or in conjunction with a complete rehabilitation program. Epidural injections for lumbar central spinal stenosis have been under debate. Many researchers compared surgical operations to epidural injections. Multiple systematic reviews and randomized trials have shown that epidural injections are useful in treating spinal stenosis pain. The aim of this study was to evaluate the pain-relieving effect of epidural steroid injection in patients with LCS. • This was a prospective study that included 25 patients suffering from LCS with pain and radiculopathy symptoms attending to orthopedic surgery department of Tanta University Hospitals All patients were subjected to full history taking, clinical examinations, laboratory investigations and plain X- ray on lumbar spine& MRI on lumbar spine that shows central stenosis with the thecal sac measuring <100mm2 in area. Summary of results • Hemoglobin level ranged from 10.9 to 16.5 g/dl with a mean value of 13.86±1.95 g/dl. • The platelet count of the study participants ranged from 279-395 x103 cell /μl with a mean value of 329.92±38.75 x103 cell /μl. • The total leucocytic count of the study participants ranged from 5.2-9.7 x103 cells/μl with a mean value of 7.16±1.42 x103 cells/μl. • Random blood glucose of the study participants ranged from 94-184 mg/dl with a mean value of 139.52±30.08 mg/dl. • Pain duration ranged from 6-45 months with a mean value of 21.44±8.86 months. • 5 (20%) participants with grade 1 LCS severity, 11 (44%) with grade 2 and 9 (36%) with grade 3. • The pretreatment VAS of the study participants ranged from 5-8 with a mean value of 6.84±0.94. • VAS score was statistically significantly lower at day one, after the first month and after three months of follow up compared to pre-treatment • VAS was also statistically significantly lower after the first month and the third month compared to day 1.